about
Dopamine promotes striatal neuronal apoptotic death via ERK signaling cascadesDopamine agonists and neuroprotection in Parkinson's disease.Do dopamine agonists or levodopa modify Parkinson's disease progression?Dopamine agonists in Parkinson's disease.Mitochondria, oxidative stress, and temporal lobe epilepsyRopinirole, a non-ergoline dopamine agonist.What causes cell death in Parkinson's disease?Recognition and management of Parkinson's disease during the premotor (prodromal) phase.Paraquat and Parkinson's disease.Non-mammalian animal models of Parkinson's disease for drug discovery.A dopamine D4 receptor antagonist attenuates ischemia-induced neuronal cell damage via upregulation of neuronal apoptosis inhibitory protein.Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells.Regional expression of dopamine D1 and D2 receptor proteins in the cerebral cortex of asphyxic newborn infants.Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.Pramipexole protects against H2O2-induced PC12 cell death.Neuroprotection in Parkinson models varies with toxin administration protocol.The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells.
P2860
Q28578325-C557780A-4064-4C0D-B913-D291504ACF8CQ35015790-28316D5D-DABD-4426-995E-1DD95422D6D0Q35015794-E9B92615-B495-411D-A903-87F302BCE7BBQ35570952-13D17AF1-D31A-4DEB-B425-8C74C85B11E1Q35609763-A89ECB4E-073E-447E-A759-F900B74E96F4Q36358853-90F4406B-0C19-45E8-950C-92B02821903FQ37363926-E952D7B4-948A-4936-8EA9-39E3D847E46EQ37507968-262B5685-29F8-4777-8CDE-55842620A986Q37679695-13013527-4723-4B10-8ACB-08C103347EC3Q38028522-5ECD76E6-ADC2-461D-927E-33957C7CE552Q40454849-25E91AE1-F5DC-45C6-8B7C-8C258A0DD10BQ40689405-A9F25C89-F4CD-4EC5-8FC2-C1E0D219F609Q46139286-DB2F21E5-4C1D-4A34-9604-05892EE343EBQ46239099-E8CEF419-FE05-4201-9ABF-816E578DAF63Q46857211-CBD9D9FF-50F8-480E-B2DB-5F76E5E0B0F6Q48343782-6E67723D-C353-48B0-A09A-57AF2E86FAC1Q48932292-1E042B7B-9E5A-4D91-921A-B9F455287859Q54579499-6ACBB7EF-4834-456E-85EF-BC4929959633
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Neuroprotection and dopamine agonists.
@ast
Neuroprotection and dopamine agonists.
@en
Neuroprotection and dopamine agonists.
@nl
type
label
Neuroprotection and dopamine agonists.
@ast
Neuroprotection and dopamine agonists.
@en
Neuroprotection and dopamine agonists.
@nl
prefLabel
Neuroprotection and dopamine agonists.
@ast
Neuroprotection and dopamine agonists.
@en
Neuroprotection and dopamine agonists.
@nl
P1433
P1476
Neuroprotection and dopamine agonists.
@en
P2093
Anthony H V Schapira
P356
10.1212/WNL.58.SUPPL_1.S9
P407
P433
P577
2002-02-01T00:00:00Z